Changes in Beneficial Ownership · 4
Invivyd, Inc.
IVVDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-15
- Issuer
- Invivyd, Inc.
- Issuer CIK
- 0001832038
- Trading symbol
- IVVD
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Duke William E.
- Reporting owner CIK
- 0001636135
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O INVIVYD, INC., 205 CHURCH STREET, NEW HAVEN, CT, 06510
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-15 | M · Form 4 | 102,000 | A | [F1] | 209,717 | D |
| Common Stock | 2026-08-17 | S · Form 4 | 22,355[F2] | D | 0.7220[F3] | 187,362 | D |
| Common Stock | 2026-08-18 | S · Form 4 | 18,425[F2] | D | 0.8429[F4] | 168,937 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-08-15 | M · Form 4 | 102,000 | D | 0.00 | [F5] | [F5] | Common Stock | 102,000 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company").↩ 1↩ 2
- F2
- The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.↩ 1↩ 2
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.682 to $0.830, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.760 to $0.872, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.↩ 1
Signature 1
- Signed
- /s/ Jill Andersen attorney-in-fact for William E. Duke
- Date
- 2026-08-18
Company context
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.